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Abstract 
 
A partial deletion of the adenovirus E3 region, comprising the overlapping 6.7K/gp19K 
genes has been described for the incorporation of therapeutic genes in “armed” 
oncolytic adenoviruses. This deletion allows the insertion of up to 2.5 kb genetic 
material into the virus and ensures strong expression of transgenes without reducing the 
replication and cytolytic potency of viruses in vitro. E3-gp19K and 6.7K proteins are 
involved in avoiding recognition and elimination of infected cells by the host immune 
system. Therefore, we have studied the effect of this deletion on the replication and 
transgene expression of the virus in immunocompetent models based on Syrian 
hamsters. Tumors were established by intrahepatic injection of pancreatic cancer cells 
with moderate (HaP-T1, HP-1) or low (H2T) permissivity for adenovirus replication. 
The wild type human adenovirus 5 (Ad5) or a modified version containing the 
luciferase gene in the E3-6.7K/gp19K locus (Ad-WTLuc) were injected intratumorally. 
We found that elimination of Ad-WTLuc was faster than Ad5 in HaP-T1 and HP-1 
tumors. In contrast, no differences were observed when the same tumor was established 
in severely immunocompromised NOD-scid IL2Rγnull mice. In addition, virus-mediated 
luciferase expression was more stable in these animals. These results suggest that the 
lack of E3-6.7K/gp19K genes may accelerate the clearance of oncolytic adenoviruses in 
some immunocompetent tumor models. 
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Introduction 
 
Experience accumulated in clinical trials on a variety of cancers with different oncolytic 
adenoviruses (conditionally replicative adenoviruses, CRAds) indicate that these agents 
are safe, but their efficacy as single agents is poor 1. Strong physical and immunological 
barriers limit the biodistribution and cytolytic effect of the viruses and virtually abolish 
the robust antitumor effect demonstrated in animal models. Therefore, new mechanisms 
to enhance their efficacy are needed. The incorporation of therapeutic genes in the 
viruses could overcome some of their limitations and provide new mechanism of action 
with potential synergistic effects 2. These genes include immunomodulatory agents, pro-
drug converting enzymes and anti-angiogenic agents, among others. Adenovirus is a 
double-stranded linear DNA virus with a compact genome and relatively strict size 
constrains for encapsidation. Only an increase of up to 5% the original size is allowed 
without reducing the efficacy of genome packaging 3. This determines that in many 
cases deletion of endogenous genes is needed in order to insert exogenous sequences 
such as long regulatory regions or transgenes. Partial or complete deletions of the E3 
region in subgroup C human adenoviruses are commonly used, because this region is 
dispensable for viral growth in vitro. However, many genes involved in protection from 
antiviral responses are located in this region 4, and there is evidence indicating that 
restoration of E3 genes increases the oncolytic potency of adenoviruses in vivo 5. The 
E3 region is a complex transcription unit in which a common promoter, alternative 
splicing and two polyadenylation signals (E3A and E3B) determine the expression of at 
least 7 different proteins 6. Most of them work in coordination for avoiding recognition 
and destruction of infected cells by the immune system in early phases of the viral cycle 
4. Only the E3-11.6K protein (adenovirus death protein, ADP) has pro-apoptotic 
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functions, but its expression is stimulated by the major late promoter after replication 
has been completed, in order to facilitate release of virions from the cell 7. The E3-
10.4K/E3-14.5K proteins (receptor internalization and degradation, RID α,β complex) 
are involved in the destruction of death receptors such as Fas and tumor necrosis factor 
(TNF)-related apoptosis-inducing ligand (TRAIL) receptors 1 and 2, thus protecting 
infected cells from apoptosis induced by the immune system 8, 9. The E3-14.7K protein 
also inhibits apoptosis induced by TNFα 10. E3-6.7K collaborates with the RID complex 
in degradation of the TRAIL receptor 2 11, and it inhibits apoptosis induced by Ca2+ 
release from the endoplasmic reticulum (ER) 12. E3-gp19K inhibits the transport of 
major histocompatibility complex class I (MHC-I) molecules form the ER to the plasma 
membrane, thus reducing the display of viral peptides and avoiding the detection of 
infected cells by specific cytotoxic T lymphocytes 13. Detailed studies of the E3 region 
have demonstrated that selective deletions can be used to insert exogenous genes 
without disrupting expression of adjacent E3 genes 14-16. This is important, since some 
E3 proteins, such as ADP, are required for maintaining the cytolytic potency of the 
virus 17. The use of endogenous promoter and polyadenylation signals reduces the 
requirement of exogenous genetic material and ensures strong expression of the 
transgenes. Following these principles, a 6.7K/gp19K deletion comprising nucleotides 
28532 to 29355 in Ad5 genome has been successfully used for the insertion of 
therapeutic genes 16. The E3-6.7K and gp19K genes are encoded by the same mRNA 
and have slightly overlapping open reading frames. Deleting both genes would allow 
the incorporation of foreign sequences up to 2.5 kb in length. However, the lack of these 
genes could accelerate the clearance of the virus and the infected cells in vivo, as 
observed for gp19K in mice 18. On the other hand, these viral functions may be 
redundant for an oncolytic adenovirus if the target cells in the tumor have developed 
 5
analogous mechanisms to prevent apoptosis and recognition by the immune system. If 
this is the case, deletion of E3-6.7K and/or gp19K would increase the cancer specificity 
of the virus. However, elucidating the influence of E3 deletions on the performance of 
oncolytic adenoviruses has been traditionally hampered by the lack of 
immunocompetent tumor models in which human adenovirus can complete its viral 
cycle. More recently, the identification of several murine cancer cell lines with various 
degrees of permissivity for adenovirus replication made possible the initial studies in 
this subject 19. Rapid clearance of viruses with extensive deletions including the RID 
complex and E3-14.7K genes was observed in these tumors, whereas a 152 bp deletion 
affecting only the gp19K gene caused no evident effect 20. Unfortunately, this small 
deletion does not provide a significant increase in the cloning capacity of the virus, and 
the influence of placing a transgene in this location is unknown. In the present work we 
have constructed a vector based in the Ad5 genome in which the firefly luciferase is 
inserted in the E3-6.7K/gp19K locus (Ad-WTLuc vector). Using a recently described 
immunocompetent model based in Syrian hamsters 21, we have studied the persistence 
of replication for Ad-WTLuc versus Ad5, and the kinetics of luciferase expression of 
Ad-WTLuc after intratumor inoculation. Replication and spread of Ad5 and related 
CRAds has been previously demonstrated in Syrian hamsters 22, 23. In our specific 
adaptation of the model, intrahepatic injection of hamster pancreatic cancer cells gives 
rise to a progressive tumor growth in the liver and extensive infiltration of surrounding 
tissues 21. Cells with different in vitro permissivity for adenoviral replication have been 
used. We describe here that immunocompetent animals eliminate Ad-WTLuc faster 
than Ad5 in tumors derived from the most permissive cells. In contrast, when the same 
tumors were established in mice with severely impaired innate and adaptive immune 
system, no differences were observed and the expression of luciferase was stabilized. 
 6
These results suggest that elimination of the E3-6.7K/gp19K genes may accelerate the 
clearance of oncolytic adenoviruses in some immunocompetent hosts. 
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Materials and Methods 
 
Cell lines and cultures. 
The human cell lines HEK 293 (ATCC#CRL-1573), A549 (lung cancer, ATCC# CCL-
185), HuH-7 (hepatocellular carcinoma, courtesy of. Dr. Brechot, INSERM, Paris, 
France), and the Syrian hamster pancreatic cancer cell lines H2T (courtesy of Dr. 
Townsend, University of Texas Medical Branch, TX, USA), HaP-T1 (German 
Collection of Micro organisms and Cell Culture, Cat. ACC 222) and HP-1 24 (Courtesy 
of Dr. Hollingsworth, University of Nebraska Medical Center, Omaha NE, USA), were 
grown in DMEM supplemented with 10% FBS, 100 U/ml penicillin, 100μg/ml 
streptomycin and 2mM L-glutamine. All cells were maintained at 37°C with 5% CO2 in 
a humidified incubator.  
 
Virus construction and production.  
Based on the previously described pSEHE2F plasmid 25, we applied standard 
subcloning techniques using intermediate plasmids to obtain a deletion of the E3-
6.7K/gp19K region flaked by ClaI sites. The firefly luciferase gene from the pGL3-
Basic plasmid (Promega) was inserted in this location using NarI sites to generate the 
pSEHE2F-Luc plasmid. In order to restore the wild type E1A and E4 regions, the 12.5 
Kb NdeI fragment from pSEHE2F-Luc plasmid that includes the transgene, was 
introduced into the pTG3602 plasmid 26 encoding the genome of Ad5. The new plasmid 
was named pAd-Luc and contains a deletion of the E3-6.7K/gp19K region with 
insertion of the luciferase gene. In order to obtain a virus with the same E3 deletion but 
no transgene, we followed a parallel subcloning procedure. In this case the 6.7K/gp19K-
deleted 12.5 Kb NdeI fragmente that was introduced in the pTG3602 plasmid lacked the 
luciferase gene, and the resulting plasmid was called pTG-DE3. The Ad-WTLuc and 
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Ad-DE3 viruses were obtained by transfection of the PacI-digested pAd-Luc and pTG-
DE3 plasmids in 293 cells, respectively. After selection of individual clones, structure 
of the modified E3 region was verified by sequencing. The Ad5 virus was obtained 
from ATCC (Catalog number VR5). The Ad-CMVLuc virus was purchased from 
Vector Biolabs (Philadelphia, USA). All viruses were amplified in 293 cells and 
purified by ultracentrifugation in CsCl gradient. Quantification of infectious units (iu) 
was done using the Adeno-X rapid titer kit (Clontech)  
 
Animal procedures.  
Liver metastases of pancreatic cancer were established in Syrian (Golden) hamsters 
(Mesocricetus Auratus; HSD HAN: AURA, 5 weeks of age, Harlan, Barcelona, Spain) 
by intrahepatic injection of 2,5x106 H2T cells, 1x106 HaP-T1 cells or 2.5x106 HP-1 cells 
following laparotomy, as previously described 21. Viruses were injected intratumorally 2 
weeks after cell implantation of HaP-T1 and HP-1 cells, and 5weeks after implantation 
of H2T cells. Injection was performed in 50 μl total volume of saline solution. Tumor 
xenografts were induced in the flank of NOD-scid IL2Rγnull mice 27 (NOD.Cg-
PrkdcscidIl2rgtm1Wjl/SzJ, stock 005557, The Jackson Laboratory) by subcutaneous 
inoculation of 106 HaP-T1 cells. When tumors reached a volume of 300-500 mm3 (V= 
(Dxd2)/2, where D and d are the major and minor diameters, respectively), animals were 
treated subcutaneously with a single dose of 600 mg/kg methyl-prednisolone acetate 
(Sanofi-Aventis). Forty eight h later, viruses were injected intratumorally as described 
above. Animals were maintained under specific pathogen-free conditions and all 
procedures were carried out following protocols approved by the local ethical 
committee in accordance with recommendations for proper care and use of laboratory 
animals.  
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In vivo bioluminiscence detection.  
Ten minutes before luciferase detection, mice and hamsters received an intraperitoneal 
injection of 100 μl or 300 μl D-Luciferin Firefly (Xenogen), respectively. Animals were 
anesthesized by intraperitoneal injection of a mixture of ketamine and xylazine and 
placed in a dark chamber connected to a cooled charge-coupled device (CCD) camera 
(IVIS, Xenogen). Photon emission was quantified and analyzed using Living Image 
Software (Xenogen). 
 
Luciferase assay in cell cultures. 
Cells were seeded in 24-well plates with 3x104 cells/well and were infected 24 h later 
with Ad5 or Ad-CMVLuc at MOI 1. The MOI (multiplicity of infection) is defined as 
the number of infectious units per cell (iu/cell). Viruses were removed 2 h later and then 
cells were washed once with PBS and incubated in DMEM supplemented with 2% FBS 
at 37°C. At different times post-infection, cells were lysed and analyzed for luciferase 
activity, using the Luciferase Assay System (Promega) as indicated by the 
manufacturer. 
 
In vitro viral replication assay (virus burst size).  
Cells (2x104 /well) were cultured in 24-well plates overnight and infected with Ad5 and 
Ad-WTLuc in DMEM supplemented with 2% FBS. The MOI was adjusted for each cell 
line in order to obtain infection of more than 50% cells. Thus, HuH-7, HaP-T1, HP-1 
and H2T cells were infected at MOI 50, and the A549 cell line was infected at MOI 25. 
Viruses were removed 2 h later and then cells were washed once with PBS and 
incubated in DMEM supplemented with 2% FBS at 37°C. Forty-eight hours later cells 
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were harvested, resuspended in PBS and lysed by three cycles of freezing and thawing. 
The amount of infective virus present in the cells was quantified by the Adeno X Rapid 
titer kit (BD Bioscience). 
 
In vitro viability assays. Cells were seeded in 96-well tissue culture plates at 
5x103cells/well and 24 h later they were infected with serial dilution of viruses. Cell 
viability was determined 5 days after infection by crystal violet staining. Briefly, cells 
were fixed for 10 min in 0,5% glutaraldehyde solution at room temperature, incubated 
for 30 min in 0,5% crystal violet solution (Sigma) and rinsed with water. Air-dried cells 
were solubilized with a 10% acetic acid solution and quantified by reading absorbance 
at 595 nm. Data were analyzed using the PrismGraphPad program. 
 
Quantification of virus production in vivo.  
At different times post-infection, tumors were frozen in liquid Nitrogen and 100-400 mg 
of tissue were homogenized in 1 ml of DMEM supplemented with 10% FBS. After 3 
cycles of freezing and thawing, samples were centrifuged at 10,000 g for 5 minutes and 
viruses in the supernatant were quantified by the Adeno X Rapid titer kit (BD 
Bioscience). 
 
RNA isolation and analysis of penton base expression by RT-PCR 
Total RNA was extracted from tumor samples using TriReagent (Sigma) according to 
the manufacturer’s instructions. Complementary DNA was synthesized from 2 μg RNA 
with M-MLV RT in the presence of RNase OUT (Invitrogen). For real-time PCR 
reaction, 5 μl of cDNA was incubated with specific primers for Adenovirus penton base 
gene (forward 5’-ACCTGGTGGACAACAAGTCA-3’; reverse 5’- 
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ACATTTGGCATGTTGGTAGGTGC-3’) using a BioRad iQ iCycler Detection System 
(BioRad Laboratories, Ltd) with SYBR green fluorophore. For sample normalization, 
the hamster β-actin cDNA was amplified using the primers 5′-
GTCGTACCACTGGCATTGTG-3′ (forward) and 5′-GTCACGCACAATTTCCCTCT-
3′ (reverse). Values are represented by 2∆Ctx104, where ∆Ct indicates the difference in 
the threshold cycle between β-actin and penton mRNAs. 
  
DNA isolation and quantification of viral genomes. 
DNA was extracted from tumor samples using the QIAmp DNA Mini Kit (Qiagen) 
according to the manufacturer’s instructions. The abundance of viral copies was 
determined by quantitative PCR from 200 ng of DNA using primers specific for the E4 
region: 5’-CTAACCAGCGTAGCCCA-3’ (forward) and 5’-
TGAGCAGCACCTTGCATTTT-3’ (reverse). A BioRad iQ iCycler Detection System 
(BioRad Laboratories, Ltd) with SYBR green fluorophore sample was used. To 
calculate the amount of copies/μg, a standard curve of purified Ad5 genomes was 
prepared. 
 
Statistical analysis. 
Statistical comparisons were done using the Mann Whitney test (GraphPad Prism 
program, GraphPad Software).  
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Results  
 
Characterization of the Ad-WTLuc virus in vitro.  
The Ad-WTLuc virus is based on the Ad5 genome, in which a portion of the E3 region 
comprising the 6.7K/gp19K genes has been deleted (nucleotides 28555 to 29355), and 
the firefly luciferase gene has been inserted. Taking into consideration this 0.8 kb 
deletion, the insertion of the luciferase gene (1.7 kb in length) is not expected to 
compromise the packaging efficiency of the virus. As previously described 16, this 
modification did not alter the expression of contiguous E3 genes such as ADP (data not 
shown). In order to identify potential alterations in the properties of the virus, first we 
compared the progeny produced by Ad-WTLuc and the parental virus Ad5 in different 
cell lines (virus burst size). To this end, human cancer cell lines HuH-7, A549 and 
hamster pancreatic cancer cell lines HaP-T1, HP-1 and H2T were infected with the 
viruses, and the amount of infective viral particles produced in a single viral cycle was 
quantified (figure 1). As previously reported for Ad5, human cell lines were the most 
efficient viral producers (up to 103 infectious units per cell, iu/cell), followed by HaP-
T1 (102 iu/cell). Although progressive viral amplification has been demonstrated in the 
H2T cells 21, virus yield was very low at 48 h, suggesting low permissivity and delayed 
viral cycle. Ad-WTLuc showed the same tendency as the parental virus, with a 
moderate reduction of virus production in some cell lines such as HuH-7, HaP-T1, HP-1 
and H2T, and slight increase in A549 cells. We next investigated if these variations had 
an impact on the ability of the virus to cause cytopathic effect and death of infected 
cells, which is one of the main properties of oncolytic adenoviruses. The same cell lines 
described above were infected with different MOIs and maintained for 5 days, in order 
to evaluate the effect of virus amplification and spread. In figure 2 we show the 
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percentage of cells that survive at the end of the experiment, compared with non-
infected controls. The results indicate that the cytolytic effect of Ad-WTLuc is not 
impaired in any of the cell lines studied.  
 
Clearance of Ad-WTLuc is accelerated in HaP-T1 tumors established in 
immunocompetent hamsters, but not in severely immunocompromised mice. 
We studied if the gene deletion/insertion introduced in the Ad-WTLuc affects the 
properties of the virus in vivo. Liver metastases of pancreatic cancer were established by 
intrahepatic injection of HaP-T1, HP-1 or H2T cells in immunocompetent Syrian 
hamsters. Once the tumors were evident (2 weeks after cell implantation for HaP-T1 
and HP-1 and 5 weeks for H2T cells), 2x109 iu of Ad-WTLuc or Ad5 were injected 
locally. Animals were sacrificed 2 or 4 days later, and the presence of infective viral 
particles was quantified in tissue homogenates from the different tumors. Two days 
after infection, it is possible that some viruses recovered from tumors correspond to 
particles retained in the tissues from the original injection, before they have infected and 
replicated in the cells. By comparison with a replication-deficient adenoviral vector, we 
determined that this represents less than 10% of viable viruses. Therefore the percentage 
of residual virus from the original input is low, and it is reduced over time. In fact, if a 
replication-deficient adenoviral vector is injected, no viable viruses can be recovered 
from HaP-T1 tumors at day 4 21. In figures 3A and 3B we show that, as previously 
described, viral production of Ad5 was not different in HaP-T1 and H2T cells in vivo 21. 
In both cases, a drop in virus content was observed from day 2 to day 4, but progeny 
production of the wid-type virus could still be detected at the latter time point. The rapid 
decrease in Ad5 production evidences the strong control that the innate immune system 
exerts on virus amplification and spread. In the case of Ad-WTLuc, a moderate 
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reduction in virus yield versus Ad5 was present already at day 2 in HaP-T1 and H2T 
tumors, probably reflecting the lower virus burst size observed in vitro. The main 
finding, however, was the rapid neutralization of Ad-WTLuc from HaP-T1 tumors 
(figure 3B). Virtually no infective particles could be recovered from these tumors at day 
4. The same result was obtained with HP-1 tumors (figure 3C). Since the sensitivity of 
this in vivo assay is low, we cannot rule out the possibility that small amounts of viruses 
are produced, but in any case the difference with Ad5 is evident. In contrast, production 
of Ad-WTLuc and Ad5 showed a similar tendency in H2T tumors (figure 3A). To 
demonstrate that the presence of the luciferase gene in the Ad-WTLuc virus is not 
responsible for its rapid clearance in HaP-T1 cells, we repeated the same experiment 
with a virus that presents the same 6.7K/gp19K deletion, but carries no transgene (Ad-
DE3). As shown in figure 3B, a rapid elimination of Ad-DE3 was also observed.  
 We next studied other indicators of viral activity in samples from HaP-T1 and 
H2T tumors in order to confirm the preferential neutralization of Ad-WTLuc in HaP-T1 
tumors. Active viral cycle was determined by analysis of late gene transcription. RNA 
was extracted from tumor samples and the mRNA corresponding to the L5-polypeptide 
III (which forms the penton base protein) was quantified by qRT-PCR (figure 4). A 
reduction of mRNA copies from day 2 to day 4 was observed in all cases, suggesting 
that viral activity is being controlled. However, blockade of Ad-WTLuc was 
significantly stronger than Ad5 in HaP-T1 tumors, in agreement with the previous 
results. Persistence of viral genomes was also determined in tumor samples from day 4, 
using qPCR for detection of the E4 gene (figure 5). Although we found great variability 
among different animals, a reduction of copy numbers was observed in HaP-T1 tumors 
treated with Ad-WTLuc, compared with Ad5. Together with the absence of viable 
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viruses recovered from these tumors, our data indicate that the spread of the virus is 
being rapidly blocked. 
 In order to determine if the immune system is responsible for this phenomenon, 
we compared the persistence of Ad5 and Ad-WTLuc in a HaP-T1 xenograft model 
established on severely immunosuppressed mice. NOD-scid IL2Rγnull mice lacking B, T 
and NK cells 27, were inoculated subcutaneously with HaP-T1 cells in order to avoid 
open surgery and deep anesthesia in these animals. Once tumors were established 
(approximately 2 weeks after inoculation), mice were treated with a single 
intraperitoneal dose of methyl-prednisolone acetate (MPA) in order to further decrease 
the number and function of the remaining leukocytes, such as macrophages 28. Forty 
eight hours after MPA injections, 5x108 iu of Ad5 or Ad-WTLuc were inoculated 
intratumorally, and animals were sacrificed 4 days later. An equal dose of the 
replication-deficient Ad-CMVLuc virus 21 was inoculated in a third group of animals to 
assess the replication-independent persistance of adenovirus in the context of 
immunocompromised mice. In figure 6 A we show the quantification of viable viruses 
recovered from the tumors. No differences between Ad5 and Ad-WTLuc were detected, 
suggesting that both viruses can replicate equally well under these circumstances. In 
addition, equivalent gene expression (penton base) and genome copy numbers were 
detected in these tumors (figure 6B). These results indicate that abrogation of the 
immune system avoids the rapid clearance of Ad-WTLuc in HaP-T1 tumors. 
Interestingly, some viable viruses were recovered from Ad-CMVLuc-treated mice 
(figure 6A). Altough the amount is significantly lower than in the case of replication-
competent viruses, Ad-CMVLuc was detected in all the animals. This is in contrast with 
data obtained in hamsters 21, and suggests that a small percentage of the original input 
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of virions remains intact in the tumor mass without infecting any cell, and can be 
extracted 4 days after inoculation in immunodeficient mice.  
Viral replication and host immune responses limit the duration of transgene 
expression mediated by Ad-WTLuc. 
Expression of transgenes inserted into the E3-6.7K/gp19K region of adenovirus is 
activated following the viral cycle 16, and is further amplified by the progressive 
increase in copy number. After lysis of the infected cells, persistence of expression will 
depend on the efficacy of virus spread. Culture of homogeneous cell populations in 
vitro favors infection of neighboring cells by the new viral progeny and allows 
progressive increase in luciferase expression. In figure 7A we show this phenomenon in 
HaP-T1 cells infected with a low MOI of Ad-WTLuc. As a negative control for 
replication, we used in parallel the Ad-CMVLuc vector, in which expression of 
luciferase is controlled by a CMV promoter. As early as 24 h post- infection, when the 
genomes of the input viruses have been replicated, lysates from cells infected with Ad-
WTLuc presented high luciferase activity. In subsequent days, the activity was 
increased despite the cytopathic effect observed in a proportion of cells in the 
monolayer. In contrast, luciferase expression mediated by Ad-CMVLuc remained 
several orders of magnitude lower than the replicative virus during all the observation 
period. In order to study the effect of physical and immunological barriers on transgene 
expression, we injected 2x109 iu of Ad-WTLuc or Ad-CMVLuc in HaP-T1 tumors 
established in the liver of Syrian hamsters. In figure 7B we represent the in vivo 
luciferase activity detected in the tumors over time, as an indicator of transgene 
expression. Day 1 refers to measurement 24 h after virus injection. As expected, the 
replication-competent virus achieved higher (at least 100-fold) activity than the 
conventional vector at early time points, probably reflecting the progression of viral 
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cycle in the cells infected by the injected virus. However, luciferase activity in Ad-
WTLuc-infected tumors showed a sharp decline in subsequent days, with 4% activity at 
day 3; 0,5% at day 7 and levels close to baseline at day 10. In order to elucidate the role 
of the immune system in this rapid inhibition, we injected Ad-WTLuc in HaP-T1 
tumors established in the NOD-scid IL2Rγnull mice treated with corticoids. Absolute 
values of luciferase activity cannot be compared, since the dose of virus administered to 
mice was lower than in hamsters (2x108 iu) in order to avoid toxicity. However, 
comparing the kinetics of luciferase activity in both types of animals (figure 7C) reveals 
a clear stabilization of transgene expression in immunodeficient mice. The percentage 
of luciferase activity is represented for each group of animals, considering 100% the 
values obtained at day 1 after infection. In contrast with the rapid inhibition in hamsters, 
we observed a small increase at day 2 in NOD-scid IL2Rγnull mice, and a gradual 
decrease in subsequent days, with maintenance of close to 20% activity at day 10 and 
approximately 3% at the end of the observation period (day 14). Animals were then 
sacrificed due to progression of tumor growth. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 18
Discussion 
 
The incorporation of therapeutic genes into CRAds generates vectors with complex 
mechanisms of action. The genomic modifications required for insertion and expression 
of exogenous material may alter the properties of the viruses at different levels, and 
understanding these changes is needed to design an efficient therapeutic strategy. In 
vivo, the role of the immune system is crucial, especially if alterations in the E3 region 
have been introduced. Selective deletions in the E3-6.7K/gp19K have been described to 
avoid major disruption of other genes in the E3 region and achieve efficient transgene 
expression in vitro 16. Here we have verified that insertion of a luciferase gene in this 
location in the context of a wild type Ad5 genome does not impair significantly the 
capacity of the virus to replicate and induce cytopathic effect. By direct comparison 
with Ad5, some variations were observed in virus burst size, but they seem to be cell 
type-specific. For the in vivo studies, we have used for the first time the Syrian hamster 
model, which allows replication of Ad5 in tumors and other organs in the context of an 
immunocompetent host 21, 22. As expected, development of an efficient adaptive 
immune response against adenovirus after a first exposure, with high titers of 
neutralizing antibodies and protection from virus re-administration was observed in 
these animals (data not shown). But in the present work we have focused on early 
events taking place few days after virus administration, when the innate immunity 
blocks the spread of replicative agents. The major finding in this study was the rapid 
inhibition of Ad-WTLuc production compared with the parental Ad5 virus in tumors 
derived from cells with moderate permissivity for adenovirus replication (HaP-T1 and 
HP-1). The functional neutralization of Ad-WTLuc 4 days after infection was confirmed 
by analysis of other parameters such as reduction of late viral gene transcription and 
copy numbers in tumor samples. This effect is mediated by the innate immune system, 
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since no difference in virus persistence was observed in NOD-scid IL2Rγnull mice 
treated with corticoids, at least in the short term. These mice lack functional T and B 
and cells due to the scid mutation; are devoid of NK cells and present dendritic cell 
dysfunctions due to a deletion in the IL2Rγ gene. In addition, they suffer alterations in 
complement activity and macrophage function derived from the NOD background 27, 29. 
In our experiments, residual activity of the immune system was transiently inhibited by 
corticoid treatment. Under these circumstances, most immunological barriers for virus 
amplification and spread should be impaired. In fact, using bioluminescence as a 
surrogate marker for Ad-WTLuc activity, we observed a clear difference between 
Syrian hamsters and NOD-scid IL2Rγnull mice harboring HaP-T1 tumors. Transgene 
expression was rapidly inhibited in hamsters, with less than 1% luciferase signal 
detectable one week after injection. In contrast, NOD-scid IL2Rγnull mice retained 
approximately 20% activity at this time point. However, it is important to note that the 
activity of Ad-WTLuc was also restricted in immunodeficient mice, with only an early 
and brief increase in expression followed by a progressive decline. This differs from the 
intrinsic capacity of the virus to propagate in vitro. These data indicate that, apart from 
the cellular components of the innate immune system, other factors limit the 
amplification of adenovirus in the microenvironment of the tumor. It seems that the 
balance between viral replication, cytopathic effect and infection of neighboring cells in 
the tumor results in a progressive loss of transgene expression that is accelerated by the 
immune system. It has been recently described that immunosuppression of Syrian 
hamsters using high dose cyclophosphamide enhances the replication of Ad5 in tumors 
and other organs 30. However, differences in viral persistence were only observed at late 
time points, and not 3 or even 9 days after infection. In agreement with these results, 
when we treated hamsters bearing HaP-T1 tumors with cyclophosphamide, we could 
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not detect any increase in the amount of Ad5 or Ad-WTLuc virus recovered from 
tumors 4 days after infection (data not shown). This suggests that efficient abrogation of 
the early response against adenovirus will be difficult in immunocompetent hosts.  
 Detailed investigation of the mechanisms responsible for the rapid blockade of 
Ad-WTLuc replication in HaP-T1 and HP-1 tumors is in progress, and awaits 
development of suitable tools for immunological studies in hamsters. It has been 
reported that a small deletion affecting only the E3-gp19K gene causes no attenuation of 
adenovirus in an immunocompetent murine model 20. This observation favors the 
hypothesis that the E3-6.7K deficiency is mostly responsible for the effect observed in 
our model. However, in vitro analysis performed so far have not demonstrated 
differences in the susceptibility to TNF receptor superfamily-induced apoptosis in HaP-
T1 and H2T cells infected with Ad5 or Ad-WTLuc (data not shown). It also remains 
unclear why the accelerated inactivation of Ad-WTLuc in HaP-T1 and HP-1 is not 
observed in hamsters harboring H2T tumors. One possibility is the delayed replication 
and cytopathic effect observed in H2T cells, which may translate into an attenuated 
immune response in vivo. This could also account for the relatively high viral progeny 
production observed in this tumors compared with the in vitro data. In summary, we 
describe that the E3-6.7K/gp19K deletion may accelerate the blockade of replication-
competent adenoviruses by the immune system in tumors derived from permissive cells. 
No alterations in other viral functions were detected, and early transgene expression was 
superior to first-generation adenoviruses. Therefore, this location may be adequate for 
the insertion of transgenes that require intense and short-term expression in vivo, such 
as vaccination and other immunogene therapy strategies against cancer.  
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Figure legends 
Figure 1. Replication of Ad5 and Ad-WTLuc in in vitro. Cancer cells from human 
(HuH-7, A549) and hamster (HaP-T1, H2T, HP-1) origin were infected for 2 h with 
Ad5 (white columns) or Ad-WTLuc (black columns) at the following MOIs: 50 for 
HuH-7, HaP-T1, HP-1 and H2T, and 25 for A549. Two days later cells were harvested 
and lysed. The amount of viable virions was quantified and is represented as iu/cell. 
 
Figure 2. Cytolytic effect of viruses. HuH-7 (A), A549 (B), H2T (C), HaP-T1 (D) and 
HP-1 cells (E) were infected with Ad5 (squares, black line) or Ad-WTLuc (triangles, 
dotted line) at the indicated MOIs and cultured for 5 days. Viable cells were stained by 
crystal violet and the percentage of surviving cells versus non-infected controls is 
represented as a sigmoidal dose-response curve. Note the different scale in the X axis 
among the cell lines.  
 
Figure 3. Viral production in tumors established in hamsters. Liver metastases of 
pancreatic cancer were established in Syrian hamsters by intrahepatic injection of H2T 
(A) HaP-T1 (B) or HP-1 (C) cells. After 2 weeks (HaP-T1, HP-1) or 4 weeks (H2T), 
hamsters were inoculated intratumorally with 2x109 iu of different viruses: Ad5 
(squares); Ad-WTLuc (triangles); or Ad-DE3 (circles). At the indicated times after 
infection, at lease 4 animals from each group were sacrificed. Tumors were lysed for 
determination of viable viral particles and represented as iu/mg tumor for each animal. 
*p<0,05 **p<0,01 
 
Figure 4. Viral gene expression in tumors established in hamsters. Ad5 (white 
colums) or Ad-WTLuc (black colums) were inoculated intratumorally at 2x109 
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iu/animal in tumors derived from HaP-T1 or H2T cells in the liver of Syrian hamsters. 
Groups of animals were sacrificed 2 or 4 days after infection, and RNA was extracted 
from tumors. Quantification of penton base mRNA was performed by qRT-PCR. 
Values are expressed as 2∆Ctx104, where ∆Ct indicates the difference in the threshold 
cycle between β-actin and penton genes. *p<0,05 ***p<0,0001 
 
Figure 5. Persistence of viral genomes in tumors established in hamsters. Ad5 
(squares) or Ad-WTLuc (triangles) were inoculated intratumorally at 2x109 iu/animal in 
tumors derived from HaP-T1 or H2T cells in the liver of Syrian hamsters. DNA was 
isolated from tumors collected 4 days after infection, and the amount of viral copies was 
determined by qPCR using primers specific for the E4 region. Values correspond to the 
number of viral copies/μg of DNA for each animal. *p<0,05. 
 
Figure 6. Viral production and persistence of viruses in HaP-T1 tumors 
established in immunodeficient mice. Tumor xenografts were induced in the flank of 
NOD-scid IL2Rγnull mice by subcutaneous inoculation of HaP-T1 cells. When tumors 
reached at least 300 mm3 volume, animals received a single dose of 600mg/Kg of 
methylprednisolone, and 48 h later Ad5 (squares), Ad-WTLuc (triangles) or Ad-
CMVLuc (circles) were injected intratumorally at 5x108 iu/mouse. Four days later, 
animals were sacrificed and tumors were collected. (A) Viable viral particles were 
determined for each tumor and represented as iu/mg. (B) Quantification of penton base 
mRNA was performed by qRT-PCR (left pair of columns). Values are expressed as 
2∆Ctx104 in the left Y axis, where ∆Ct indicates the difference in the threshold cycle 
between β-actin and penton genes. The amount of viral copies was determined by qPCR 
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using primers specific for the E4 region (right pair of columns). Values in the right Y 
axis correspond to the number of viral copies/μg of DNA for each animal. 
 
Figure 7. Transgene expression of Ad-WTLuc in vitro and in vivo. (A) HaP-T1 cells 
were infected with Ad-WTLuc (black columns) or Ad-CMVLuc (grey columns) at a 
MOI of 1. Cells were collected at different times post-infection, and luciferase activity 
was measured. Values correspond to luciferase units/μg protein. (B) A single dose of 
2x109 iu Ad-WTLuc (black columns) or Ad-CMVLuc (grey columns) was injected in 
HaP-T1 tumors established in the liver of Syrian hamsters. In vivo luciferase activity 
was analyzed over time and represented as photons/sec. (C) A single dose of 2x108 iu 
Ad-WTLuc was injected in subcutaneous HaP-T1 tumors established in methyl-
prednisolone-treated NOD-scid IL2Rγnull mice. The evolution of in vivo luciferase 
activity was monitored and represented as percentage from day 1 after infection (black 
squares). Initial luminescence was 3x108 photons/sec. Kinetics of luciferase activity in 
hamsters described in panel B are included as comparison (black triangles).  
 
 







